<DOC>
	<DOCNO>NCT00364754</DOCNO>
	<brief_summary>This Phase I , multi-centre , open-label , cross-over pharmacokinetic study design investigate whether co-administration fix dose tesmilifene alters plasma pharmacokinetics standard regimen epirubicin and/or principle metabolite , epirubicinol cyclophosphamide .</brief_summary>
	<brief_title>Pharmacokinetic Study Tesmilifene ( YMB1002 ) Plus Epirubicin Cyclophosphamide Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase I , multi-centre , open-label , cross-over pharmacokinetic study design investigate whether co-administration fix dose tesmilifene alters plasma pharmacokinetics standard regimen epirubicin and/or 's principle metabolite , epirubicinol cyclophosphamide . The plasma pharmacokinetics epirubicin/epirubicinol cyclophosphamide give alone concurrently tesmilifene examine . Safety information tesmilifene/ epirubicin cyclophosphamide combination epirubicin cyclophosphamide alone patient population also collect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tesmilifene</mesh_term>
	<criteria>1 . Patients document histological/cytological proof metastatic and/or recurrent breast cancer suitable treatment epirubicin cyclophosphamide . Patients locally advance inoperable lesion also eligible . 2 . Previous therapy : If patient hormoneresponsive disease , randomization permit 6 week antihormonal therapy 5 half life ( whichever short ) unless evidence progressive disease case patient could randomize early . No previous exposure anthracycline/anthracenedionebased chemotherapy . Patients may receive nonanthracycline/anthracenedione base adjuvant chemotherapy , complete minimum 4 week prior randomization . Patients must previous chemotherapy metastatic disease . Immunotherapy experimental therapy must stop minimum 4 week prior randomization . A minimum four week must elapse end prior radiotherapy randomization . Exceptions make , however , palliative radiotherapy involve 30 % bone marrow . 3 . ECOG status 0 , 1 2 . 4 . Female , age 18 55 year . 5 . Life expectancy least 6 month . 6 . Patients must willing able follow instruction make require study visit . 7 . Patients must willing able give write consent participate study . 8 . Disease free interval less equal 36 month . 9 . Normal organ marrow function 10 . Negative serum urine pregnancy test within 72 hour prior randomization must medically recognize form birth control approve investigator . 11 . Negative blood test HIV Hepatitis B C within 4 week prior randomisation . 1 . Previous malignancy , exclude curatively treat basal squamous cell carcinoma skin insitu cervical cancer cancer treat five year prior study entry presume cure . 2 . Known brain meningeal metastases 3 . Use chemotherapeutic agent malignancy within 4 week prior study entry recover adverse event due agent administer 4 week earlier . 4 . Treatment investigational drug within precede four week . 5 . Pregnant breastfeeding female . 6 . History seizure disorder . 7 . Clinical evidence congestive heart failure , recent myocardial infarction within 6 month , uncontrolled arterial hypertension , unstable angina , cardiomyopathy arterial ventricular clinically significant arrhythmia even medically control . 8 . Clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , respiratory , neurologic , psychiatric , immunologic , gastrointestinal , haematologic , metabolic condition laboratory abnormality , opinion Investigator Medical Director YM BioSciences Inc. , make patient unsuitable participation study . 9 . Known allergy hypersensitivity test article ingredient . 10 . Patients COX 1 2 prostaglandin inhibitor ( e.g . ASA , NSAID 's , Celcbrex® , Vioxx® ) comply guideline concomitant therapy . 11 . Patients H1 antagonist detail protocol comply guideline concomitant therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Tesmilifene</keyword>
	<keyword>DPPE</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>